Motor Neuron Disease

Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease in North America, is a progressive neurodegenerative disorder that destroys the motor neurons — the nerve cells responsible for controlling voluntary muscle movement. The disease affects both upper motor neurons in the brain and lower motor neurons in the spinal cord, leading to progressive muscle weakness, atrophy, and eventually paralysis. It does not typically affect cognitive function, sensory perception, or autonomic systems. The mind remains intact while the body fails.

The etiology of ALS remains largely unknown. Approximately 5–10% of cases are familial, linked to mutations in genes such as SOD1, C9orf72, TARDBP, and FUS. The remaining 90–95% are sporadic, with no clear genetic cause. Proposed mechanisms include glutamate excitotoxicity, mitochondrial dysfunction, protein aggregation, oxidative stress, and neuroinflammation. No single mechanism has been established as primary, and the disease's heterogeneity suggests that multiple pathways may converge on the same clinical outcome.

Diagnosis and Course

Diagnosis is clinical, supported by electromyography, nerve conduction studies, and magnetic resonance imaging to rule out mimics such as cervical spondylosis or multifocal motor neuropathy. There is no definitive biomarker, and misdiagnosis is common in early stages. The median survival from symptom onset is three to five years, though 10% of patients survive more than ten years. Stephen Hawking, diagnosed at age 21 in 1963, survived for 55 years — an extreme outlier whose longevity has been attributed to his young age at onset, the slow progression of his particular variant, and exceptional medical care.

Riluzole, approved in 1995, extends survival by approximately two to three months by reducing glutamate excitotoxicity. Edaravone, approved in 2017, slows functional decline in early-stage patients by scavenging free radicals. In 2023, tofersen became the first gene-specific therapy, targeting SOD1-mutant ALS. These treatments are modest. They do not halt the disease.

Theoretical Significance

ALS occupies an unusual position at the intersection of clinical neurology, molecular biology, and systems neuroscience. The selective vulnerability of motor neurons — among the largest cells in the nervous system, with axons extending from the cortex to the extremities — has been proposed as a model for understanding axonal transport failure and the dying-back hypothesis of neurodegeneration. The disease also raises questions about the relationship between the brain and the body that transcend clinical medicine. The preservation of consciousness in a progressively paralyzed body has made ALS a focus of research into brain-computer interfaces, locked-in syndrome, and the neural basis of communication.

ALS is not merely a medical tragedy. It is a boundary case — a disease that progressively strips away the body while leaving the mind intact, forcing questions about embodiment, identity, and the limits of human adaptation that no other neurological disorder raises with such clarity. The patient who survives decades with ALS is not simply surviving; they are redefining what a human being can be with fewer and fewer biological resources.